{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-300141","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2022-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.860743+00:00","generated_at":"2026-06-21T08:23:13.098106+00:00","sec_items":["1.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phoenix Biotech Acquisition Corp. and Intrinsic Medicine mutually terminate business combination agreement","bullets":["Business combination agreement terminated on December 6, 2022 due to current market conditions.","No termination fee or other payment due from any party as a result of the termination.","Sponsor support agreement and intrinsic support agreements automatically terminated.","PBAX CEO Chris Ehrlich expressed continued optimism about Intrinsic's platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-300141","json":"https://secwatch.observer/filing/0001193125-22-300141.json","markdown":"https://secwatch.observer/filing/0001193125-22-300141.md","text":"https://secwatch.observer/filing/0001193125-22-300141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000119312522300141/0001193125-22-300141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000119312522300141/d421267d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:23:13.098106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54822bd9f6645915a3ad2051db72b244026e5ff3","claim":"CERO THERAPEUTICS HOLDINGS, INC. terminated Sponsor Support Agreement with Phoenix Biotech Sponsor, LLC (effective 2022-12-06).","evidence_excerpt":"The Sponsor Support Agreement, dated as of October 30, 2022 (the “ Sponsor Support Agreement ”), by and among the Company, Intrinsic, Phoenix Biotech Sponsor, LLC, a Delaware limited liability company, and each of the Company’s officers and directors, automatically terminated in accordance with its terms upon the termination of the Business Combination Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000119312522300141/0001193125-22-300141-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Phoenix Biotech Sponsor, LLC"},{"label":"Effective","value":"2022-12-06"}],"fact_type":"material_agreement"},{"claim_id":"bfb113902a914922ec1dd9a8a7af73c06c54a6cd","claim":"CERO THERAPEUTICS HOLDINGS, INC. terminated Business Combination Agreement with Intrinsic Medicine, Inc. (effective 2022-12-06).","evidence_excerpt":"On December 6, 2022 (the “ Termination Date ”), the Company and Intrinsic entered into a Termination Agreement (the “ Termination Agreement ”), a copy of which is filed as Exhibit 2.1 hereto, which among other things provides for the mutual termination of the Business Combination Agreement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000119312522300141/0001193125-22-300141-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Intrinsic Medicine, Inc."},{"label":"Effective","value":"2022-12-06"}],"fact_type":"material_agreement"},{"claim_id":"f468ec283bdc2cc44fee57c274f15f9f6acb87d5","claim":"CERO THERAPEUTICS HOLDINGS, INC. terminated Intrinsic Support Agreements with certain Intrinsic stockholders (effective 2022-12-06).","evidence_excerpt":"The support agreements, dated as of October 30, 2022 (the “ Intrinsic Support Agreements ”), by and among the Company, Intrinsic and certain Intrinsic stockholders, automatically terminated in accordance with their terms upon the termination of the Business Combination Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000119312522300141/0001193125-22-300141-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"certain Intrinsic stockholders"},{"label":"Effective","value":"2022-12-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}